COMUNICADO: Gracias a Xenical(R), los adolescentes con obesidad pierden peso con mayor rapidez (y 2)

7. Must A. Morbidity and mortality associated with elevated body weight in children and adolescents. Clin Nutr. 1996;63 (suppl 3): S445-S447.

8. Torgerson JS, et al. XENDOS: a randomised study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 2004;27(1):155-61

9. Broom I, Wilding J, Stott P, et al. Randomised trial of the effect of orlistat on body weight and cardiovascular disease risk profile in obese patients: UK Multimorbidity Study. Int J Clin Pract. 2002. 56(7): 494-9.

10. Bakris G, Calhoun D, Egan B, et al. Orlistat improves blood pressure control in obese subjects with treated but inadequately controlled hypertension. J Hypertens. 2002. 20 (11):2257-67.

11. Holt R, et al. Orlistat reduces features of the metabolic syndrome: the XENDOS study. Diabetes Obes Metab. 2003. 5(5):356.

Para más información, contacte con: Liz Gofton, Shire Health International, tel: +44-207-108-6518, móvil: +44-798-082-4860, E-mail: liz.gofton@shirehealthinternational.com. Dr. Paul King, F. Hoffmann-La Roche Ltd, Basel, Suiza, móvil: +41-79-7888270

WhatsAppFacebookTwitterLinkedinBeloudBluesky